Clinical trial NCT00078455: Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
Official title: A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Non-Small-Cell Lung Carcinoma
Keywords: NSCLC
Non-small Cell Lung Cancer
Non-small Cell Lung Carcinoma
Locally Advanced NSCLC
Metastatic NSCLC
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2004-03-01
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase II, non-randomized, open label study of ILX651 in patients with locally advanced or metastatic non-small cell lung carcinoma (NSCLC). Approximately 60 patients will be enrolled in this study that is expected to last 18 months. All patients will be treated with ILX651 administered intravenously (IV) daily for 5 consecutive days once every 21 days. The primary objective of this study is to determine the overall response rate. The secondary objectives are to determine the progression free survival, duration of response, time to tumor progression, survival, safety/tolerability of ILX651, and to evaluate pharmacokinetic profile.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed locally advanced or metastatic NSCLC previously treated with 2 prior chemotherapy regimens (not including prior adjuvant therapy for stage I or II disease).
* Disease recurrence or progression after prior therapy with a platinum-based and a taxane-based regimen, given either concurrently or separately.
* Measurable disease. Measurable lesions should be outside the field of radiation. Where measurable lesions are within a previously irradiated field, there must be objective evidence of progression of the lesion prior to patient enrollment.
* Male or female patients greater than or equal to 18 years of age.
* ECOG performance status of 0 or 1.
* Must have adequate organ and immune system function as indicated by the following laboratory values, obtained less than or equal to 2 weeks prior to registration: A. Absolute neutrophil count (ANC) greater than or equal to 1.5 x 1,000,000,000. B. Hemoglobin greater than or equal to 9.0 g/dL. C. Platelet count greater than or equal to 100 x 1,000,000,000/L. D. Serum creatinine or calculated creatinine clearance less than or equal to 1.5 mg/dL or greater than or equal to 60 mL/min. E. Serum total bilirubin within limits of normal values. F. AST and ALT less than or equal to 2 times the upper limit of normal (ULN). G. Alkaline phosphatase within limits of normal values
* Anti-cancer therapy, major surgery, or irradiation must have been completed at least 3 weeks before enrollment in this study. Patient must have recovered from the acute side effects incurred as a result of previous therapy.
* Female patients with childbearing potential must have a negative pregnancy test within 7 days of study enrollment. Men and women of reproductive potential must use an effective contraceptive method while enrolled in the study.
* Signed informed consent (includes HIPAA authorization).

Exclusion Criteria:

* Patients with uncontrolled congestive heart failure or angina, patients with a history of myocardial infarction within 2 months of enrollment, or patients with cardiac functional capacity Class III or IV as defined by the New York Heart Association Classification.
* Previously treated with \> 2 prior chemotherapy regimens for advanced or metastatic disease.
* Prior radiotherapy to the only site of measurable disease.
* Known hypersensitivity to study drug or its analogs.
* Use of investigational agents within previous 30 days.
* Known, active infection, or known HIV positive or presence of an AIDS related illness.
* Active secondary malignancy except minor skin cancers.
* Presence of symptomatic active brain metastases, including leptomeningeal involvement.
* Any significant concurrent disease or illness, or psychiatric disorders or alcohol or chemical abuse that would, in the opinion of the investigator, compromise patient safety or compliance, or interfere with the interpretation of study results.
* Pregnant or lactating females.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Tucson
country: United States
facility: US Oncology/ Arizona Clinical Research Center
state: Arizona
city: Santa Monica
country: United States
facility: Cancer Institute Medical Group
state: California
city: Aurora
country: United States
facility: Anshutz Cancer Pavillion
state: Colorado
city: Ocala
country: United States
facility: US Oncology / Ocala Oncology
state: Florida
city: Indianapolis
country: United States
facility: US Oncology / Central Indiana Cancer Centers
state: Indiana
city: New Orleans
country: United States
facility: Hematology and Oncology Specialists
state: Louisiana
city: Nashville
country: United States
facility: Sarah Cannon Cancer Center
state: Tennessee
city: Dallas
country: United States
facility: US Oncology / Texas Cancer Center
state: Texas
city: Lubbock
country: United States
facility: Joe Arrington Cancer Center
state: Texas
city: Tyler
country: United States
facility: US Oncology / Tyler Cancer Center
state: Texas
Study officials:
References: